Showing results (801-810 of 857) with videos related to
Sort By:
Pageof 86
The New England Journal of Medicine|November 3, 2009
A trial of darbepoetin alfa in type 2 diabetes and chronic kidney diseaseMarc A Pfeffer, Emmanuel A Burdmann, Chao-Yin Chen, et al.American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|December 23, 2018
Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)Finnian R Mc Causland, Brian Claggett, Emmanuel A Burdmann, et al.American Journal of Nephrology|November 21, 2022
Baseline Clinical Characteristics and Complement Biomarkers of Patients with C3 Glomerulopathy Enrolled in Two Phase 2 Studies Investigating the Factor D Inhibitor DanicopanSteven D Podos, Howard Trachtman, Gerald B Appel, et al.Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|November 1, 2021
Neuropeptide Y as a risk factor for cardiorenal disease and cognitive dysfunction in chronic kidney disease: translational opportunities and challengesCarmine Zoccali, Alberto Ortiz, Inga Arune Blumbyte, et al.Kidney International. Supplement|August 20, 2005
Prevention of chronic kidney and vascular disease: toward global health equity--the Bellagio 2004 DeclarationJohn H Dirks, Dick de Zeeuw, Sanjay K Agarwal, et al.Plos Medicine|January 14, 2021
Recognition and management of community-acquired acute kidney injury in low-resource settings in the ISN 0by25 trial: A multi-country feasibility studyEtienne Macedo, Ulla Hemmila, Sanjib Kumar Sharma, et al.Journal of the Endocrine Society|April 27, 2018
Blood Pressure and Metabolic Effects of Acetyl-l-Carnitine in Type 2 Diabetes: DIABASI Randomized Controlled TrialAneliya Parvanova, Matias Trillini, Manuel A Podestà, et al.Journal of Immunology (Baltimore, Md. : 1950)|March 4, 2018
Statistical Validation of Rare Complement Variants Provides Insights into the Molecular Basis of Atypical Hemolytic Uremic Syndrome and C3 GlomerulopathyAmy J Osborne, Matteo Breno, Nicolo Ghiringhelli Borsa, et al.Clinical Journal of the American Society of Nephrology : CJASN|February 8, 2023
Evaluation of Variation in the Performance of GFR Slope as a Surrogate End Point for Kidney Failure in Clinical Trials that Differ by Severity of CKDWillem Collier, Lesley A Inker, Benjamin Haaland, et al.American Journal of Nephrology|November 24, 2022
Clinical Outcomes of Patients with C3G or IC-MPGN Treated with the Factor D Inhibitor Danicopan: Final Results from Two Phase 2 StudiesCarla Nester, Gerald B Appel, Andrew S Bomback, et al.Pageof 86